AI Insight
Researchers have identified a protein called NFIL3 that causes CAR T-cells to become exhausted and lose their ability to fight cancer over time. In animal studies, when NFIL3 was disabled in these engineered immune cells, they maintained their cancer-fighting capabilities for longer periods and showed improved tumor control. This discovery suggests that NFIL3 may be a key limiting factor in the long-term effectiveness of CAR T-cell therapy.
Why it matters
This finding could lead to more effective CAR T-cell therapies by providing a specific target to enhance treatment durability. If NFIL3 inhibition proves successful in clinical trials, it may help extend remission periods and improve outcomes for cancer patients receiving this immunotherapy.
Understand the Science
A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their cancer-fighting power over time. When NFIL3 was disabled, the cells remained stronger for longer and controlled tumors more effectively in animal models.
Source: A single protein may be holding back CAR T cancer therapy